Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis
BackgroundOxidized lipid mediators such as eicosanoids play a central role in the inflammatory response associated with tuberculosis (TB) pathogenesis. Diabetes mellitus (DM) leads to marked changes in lipid mediators in persons with TB. However, the associations between diabetes-related changes in...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.919802/full |
| _version_ | 1828516757574254592 |
|---|---|
| author | María B. Arriaga María B. Arriaga María B. Arriaga María B. Arriaga Farina Karim Artur T.L. Queiroz Artur T.L. Queiroz Mariana Araújo-Pereira Mariana Araújo-Pereira Mariana Araújo-Pereira Beatriz Barreto-Duarte Beatriz Barreto-Duarte Beatriz Barreto-Duarte Caio Sales Caio Sales Mahomed-Yunus S. Moosa Matilda Mazibuko Ginger L. Milne Fernanda Maruri Carlos Henrique Serezani John R. Koethe Marina C. Figueiredo Afrânio L. Kritski Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Valeria C. Rolla Timothy R. Sterling Alasdair Leslie Alasdair Leslie Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade the RePORT Brazil and South Africa consortia Alice M. S. Andrade Michael S. Rocha Vanessa Nascimento Juan M. Cubillos-Angulo Hayna Malta-Santos Jéssica Rebouças-Silva Sayonara M. Viana Saulo R. N. Santos André Ramos Alysson G. Costa Jaquelane Silva Jamile G. de Oliveira, Secretaria Aline Benjamin Adriano Gomes-Silva Flavia M. Sant’Anna Francine P. Ignácio Maria Cristina Lourenço Elisangela C. Silva Adriana S. R. Moreira Mayla Mello |
| author_facet | María B. Arriaga María B. Arriaga María B. Arriaga María B. Arriaga Farina Karim Artur T.L. Queiroz Artur T.L. Queiroz Mariana Araújo-Pereira Mariana Araújo-Pereira Mariana Araújo-Pereira Beatriz Barreto-Duarte Beatriz Barreto-Duarte Beatriz Barreto-Duarte Caio Sales Caio Sales Mahomed-Yunus S. Moosa Matilda Mazibuko Ginger L. Milne Fernanda Maruri Carlos Henrique Serezani John R. Koethe Marina C. Figueiredo Afrânio L. Kritski Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Valeria C. Rolla Timothy R. Sterling Alasdair Leslie Alasdair Leslie Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade the RePORT Brazil and South Africa consortia Alice M. S. Andrade Michael S. Rocha Vanessa Nascimento Juan M. Cubillos-Angulo Hayna Malta-Santos Jéssica Rebouças-Silva Sayonara M. Viana Saulo R. N. Santos André Ramos Alysson G. Costa Jaquelane Silva Jamile G. de Oliveira, Secretaria Aline Benjamin Adriano Gomes-Silva Flavia M. Sant’Anna Francine P. Ignácio Maria Cristina Lourenço Elisangela C. Silva Adriana S. R. Moreira Mayla Mello |
| author_sort | María B. Arriaga |
| collection | DOAJ |
| description | BackgroundOxidized lipid mediators such as eicosanoids play a central role in the inflammatory response associated with tuberculosis (TB) pathogenesis. Diabetes mellitus (DM) leads to marked changes in lipid mediators in persons with TB. However, the associations between diabetes-related changes in lipid mediators and clearance of M. tuberculosis (Mtb) among persons on anti-TB treatment (ATT) are unknown. Quantification of urinary eicosanoid metabolites can provide insights into the circulating lipid mediators involved in Mtb immune responses.MethodsWe conducted a multi-site prospective observational study among adults with drug-sensitive pulmonary TB and controls without active TB; both groups had sub-groups with or without dysglycemia at baseline. Participants were enrolled from RePORT-Brazil (Salvador site) and RePORT-South Africa (Durban site) and stratified according to TB status and baseline glycated hemoglobin levels: a) TB-dysglycemia (n=69); b) TB-normoglycemia (n=64); c) non-TB/dysglycemia (n=31); d) non-TB/non-dysglycemia (n=29). We evaluated the following urinary eicosanoid metabolites: 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (major urinary metabolite of prostaglandin E2, PGE-M), tetranor-PGE1 (metabolite of PGE2, TN-E), 9α-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (metabolite of PGD2, PGD-M), 11-dehydro-thromboxane B2 (11dTxB2), 2,3-dinor-6-keto-PGF1α (prostaglandin I metabolite, PGI-M), and leukotriene E4 (LTE4). Comparisons between the study groups were performed at three time points: before ATT and 2 and 6 months after initiating therapy.ResultsPGE-M and LTE4 values were consistently higher at all three time-points in the TB-dysglycemia group compared to the other groups (p<0.001). In addition, there was a significant decrease in PGI-M and LTE4 levels from baseline to month 6 in the TB-dysglycemia and TB-normoglycemia groups. Finally, TB-dysglycemia was independently associated with increased concentrations of PGD-M, PGI-M, and LTE4 at baseline in a multivariable model adjusting for age, sex, BMI, and study site. These associations were not affected by HIV status.ConclusionThe urinary eicosanoid metabolite profile was associated with TB-dysglycemia before and during ATT. These observations can help identify the mechanisms involved in the pathogenesis of TB-dysglycemia, and potential biomarkers of TB treatment outcomes, including among persons with dysglycemia. |
| first_indexed | 2024-12-11T18:32:33Z |
| format | Article |
| id | doaj.art-435ed61dfa08482680dc31a82c9cdb0f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T18:32:33Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-435ed61dfa08482680dc31a82c9cdb0f2022-12-22T00:54:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.919802919802Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary TuberculosisMaría B. Arriaga0María B. Arriaga1María B. Arriaga2María B. Arriaga3Farina Karim4Artur T.L. Queiroz5Artur T.L. Queiroz6Mariana Araújo-Pereira7Mariana Araújo-Pereira8Mariana Araújo-Pereira9Beatriz Barreto-Duarte10Beatriz Barreto-Duarte11Beatriz Barreto-Duarte12Caio Sales13Caio Sales14Mahomed-Yunus S. Moosa15Matilda Mazibuko16Ginger L. Milne17Fernanda Maruri18Carlos Henrique Serezani19John R. Koethe20Marina C. Figueiredo21Afrânio L. Kritski22Marcelo Cordeiro-Santos23Marcelo Cordeiro-Santos24Marcelo Cordeiro-Santos25Valeria C. Rolla26Timothy R. Sterling27Alasdair Leslie28Alasdair Leslie29Bruno B. Andrade30Bruno B. Andrade31Bruno B. Andrade32Bruno B. Andrade33Bruno B. Andrade34Bruno B. Andrade35the RePORT Brazil and South Africa consortiaAlice M. S. AndradeMichael S. RochaVanessa NascimentoJuan M. Cubillos-AnguloHayna Malta-SantosJéssica Rebouças-SilvaSayonara M. VianaSaulo R. N. SantosAndré RamosAlysson G. CostaJaquelane SilvaJamile G. de Oliveira, SecretariaAline BenjaminAdriano Gomes-SilvaFlavia M. Sant’AnnaFrancine P. IgnácioMaria Cristina LourençoElisangela C. SilvaAdriana S. R. MoreiraMayla MelloLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BrazilMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilFaculdade de Medicina, Universidade Federal da Bahia, Salvador, BrazilInstituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, PeruDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South AfricaMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilCenter of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BrazilLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BrazilMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilFaculdade de Medicina, Universidade Federal da Bahia, Salvador, BrazilLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BrazilMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, BrazilMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, BrazilAfrica Health Research Institute, Durban, South AfricaDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South AfricaDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States1Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil2Fundação Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil3Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil4Universidade Federal do Amazonas, Manaus, Brazil5Laboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United StatesAfrica Health Research Institute, Durban, South Africa6Division of Infection and Immunity, University College London, London, United KingdomLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BrazilMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, BrazilFaculdade de Medicina, Universidade Federal da Bahia, Salvador, BrazilCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States7Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, BrazilBackgroundOxidized lipid mediators such as eicosanoids play a central role in the inflammatory response associated with tuberculosis (TB) pathogenesis. Diabetes mellitus (DM) leads to marked changes in lipid mediators in persons with TB. However, the associations between diabetes-related changes in lipid mediators and clearance of M. tuberculosis (Mtb) among persons on anti-TB treatment (ATT) are unknown. Quantification of urinary eicosanoid metabolites can provide insights into the circulating lipid mediators involved in Mtb immune responses.MethodsWe conducted a multi-site prospective observational study among adults with drug-sensitive pulmonary TB and controls without active TB; both groups had sub-groups with or without dysglycemia at baseline. Participants were enrolled from RePORT-Brazil (Salvador site) and RePORT-South Africa (Durban site) and stratified according to TB status and baseline glycated hemoglobin levels: a) TB-dysglycemia (n=69); b) TB-normoglycemia (n=64); c) non-TB/dysglycemia (n=31); d) non-TB/non-dysglycemia (n=29). We evaluated the following urinary eicosanoid metabolites: 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (major urinary metabolite of prostaglandin E2, PGE-M), tetranor-PGE1 (metabolite of PGE2, TN-E), 9α-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (metabolite of PGD2, PGD-M), 11-dehydro-thromboxane B2 (11dTxB2), 2,3-dinor-6-keto-PGF1α (prostaglandin I metabolite, PGI-M), and leukotriene E4 (LTE4). Comparisons between the study groups were performed at three time points: before ATT and 2 and 6 months after initiating therapy.ResultsPGE-M and LTE4 values were consistently higher at all three time-points in the TB-dysglycemia group compared to the other groups (p<0.001). In addition, there was a significant decrease in PGI-M and LTE4 levels from baseline to month 6 in the TB-dysglycemia and TB-normoglycemia groups. Finally, TB-dysglycemia was independently associated with increased concentrations of PGD-M, PGI-M, and LTE4 at baseline in a multivariable model adjusting for age, sex, BMI, and study site. These associations were not affected by HIV status.ConclusionThe urinary eicosanoid metabolite profile was associated with TB-dysglycemia before and during ATT. These observations can help identify the mechanisms involved in the pathogenesis of TB-dysglycemia, and potential biomarkers of TB treatment outcomes, including among persons with dysglycemia.https://www.frontiersin.org/articles/10.3389/fimmu.2022.919802/fulldysglycemiaMycobacterium tuberculosisurinary eicosanoidslipid mediatorsanti-tuberculosis treatment |
| spellingShingle | María B. Arriaga María B. Arriaga María B. Arriaga María B. Arriaga Farina Karim Artur T.L. Queiroz Artur T.L. Queiroz Mariana Araújo-Pereira Mariana Araújo-Pereira Mariana Araújo-Pereira Beatriz Barreto-Duarte Beatriz Barreto-Duarte Beatriz Barreto-Duarte Caio Sales Caio Sales Mahomed-Yunus S. Moosa Matilda Mazibuko Ginger L. Milne Fernanda Maruri Carlos Henrique Serezani John R. Koethe Marina C. Figueiredo Afrânio L. Kritski Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Marcelo Cordeiro-Santos Valeria C. Rolla Timothy R. Sterling Alasdair Leslie Alasdair Leslie Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade Bruno B. Andrade the RePORT Brazil and South Africa consortia Alice M. S. Andrade Michael S. Rocha Vanessa Nascimento Juan M. Cubillos-Angulo Hayna Malta-Santos Jéssica Rebouças-Silva Sayonara M. Viana Saulo R. N. Santos André Ramos Alysson G. Costa Jaquelane Silva Jamile G. de Oliveira, Secretaria Aline Benjamin Adriano Gomes-Silva Flavia M. Sant’Anna Francine P. Ignácio Maria Cristina Lourenço Elisangela C. Silva Adriana S. R. Moreira Mayla Mello Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis Frontiers in Immunology dysglycemia Mycobacterium tuberculosis urinary eicosanoids lipid mediators anti-tuberculosis treatment |
| title | Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis |
| title_full | Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis |
| title_fullStr | Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis |
| title_full_unstemmed | Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis |
| title_short | Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis |
| title_sort | effect of dysglycemia on urinary lipid mediator profiles in persons with pulmonary tuberculosis |
| topic | dysglycemia Mycobacterium tuberculosis urinary eicosanoids lipid mediators anti-tuberculosis treatment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.919802/full |
| work_keys_str_mv | AT mariabarriaga effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT mariabarriaga effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT mariabarriaga effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT mariabarriaga effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT farinakarim effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT arturtlqueiroz effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT arturtlqueiroz effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marianaaraujopereira effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marianaaraujopereira effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marianaaraujopereira effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT beatrizbarretoduarte effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT beatrizbarretoduarte effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT beatrizbarretoduarte effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT caiosales effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT caiosales effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT mahomedyunussmoosa effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT matildamazibuko effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT gingerlmilne effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT fernandamaruri effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT carloshenriqueserezani effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT johnrkoethe effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marinacfigueiredo effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT afraniolkritski effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marcelocordeirosantos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marcelocordeirosantos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT marcelocordeirosantos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT valeriacrolla effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT timothyrsterling effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT alasdairleslie effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT alasdairleslie effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT brunobandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT thereportbrazilandsouthafricaconsortia effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT alicemsandrade effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT michaelsrocha effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT vanessanascimento effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT juanmcubillosangulo effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT haynamaltasantos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT jessicareboucassilva effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT sayonaramviana effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT saulornsantos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT andreramos effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT alyssongcosta effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT jaquelanesilva effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT jamilegdeoliveirasecretaria effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT alinebenjamin effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT adrianogomessilva effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT flaviamsantanna effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT francinepignacio effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT mariacristinalourenco effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT elisangelacsilva effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT adrianasrmoreira effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis AT maylamello effectofdysglycemiaonurinarylipidmediatorprofilesinpersonswithpulmonarytuberculosis |